摘要
目的观察恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化临床疗效。方法:将56例乙肝肝硬化代偿期患者随机分为恩替卡韦与复方鳖甲软肝片联合治疗组及恩替卡韦单药组,分别于治疗前和治疗后48周检测肝功能、HBV-DNA、血清肝纤维化指标及肝脏瞬时弹性成像测定。结果:2组患者治疗后肝功能好转、HBV-DNA水平下降,2组比较无明显差异(P>0.05),但联合治疗组肝纤维化程度改善更明显(P<0.05)。结论:恩替卡韦与复方鳖甲软肝片联合治疗在抗纤维化程度方面优于单用恩替卡韦。
Objective： To explore curative effects of entecavir and compoundBieJiaRuanGantablets in treat-ing decompensated liver cirrhosis of hepatitis B. Methods： All 56 patients were randomized into 29 cases of the treat-ment group and 27 cases of the control group, liver function, HBV-DNA, the indexes of liver fibrosis in the serum and liver fibroScan were detected before treating and in 48 weeks after treating. Results： After treating, liver func-tions were improved, the levels of HBV-DNA were decreased in both groups, there was no significant difference （P〉0.05）; the improvements of liver fibrosis in the treatment group were more remarkable （P〈0.05）. Conclusion： Curative effects of entecavir and compoundBieJiaRuanGantablets are superior to the effects of entecavir in treating fibrosis.
出处
《西部中医药》
2014年第7期84-86,共3页
Western Journal of Traditional Chinese Medicine
关键词
乙型肝炎
肝硬化
肝纤维化
恩替卡韦片
复方鳖甲软肝片
liver cirrhosis of hepatitis B
liver fibrosis
entecavir
compoundBieJiaRuanGantablets
